Company profile

Oncobit AG

To offer personalized therapies, diagnostics must keep pace to provide the necessary information. Oncobit is a MedTech spin-off from the University of Zurich, developing critical precision diagnostic and monitoring solutions to enable the cancer treatment of the future. A unique combination of technical know-how, proprietary software and close clinical collaborations, allows us to bring more comprehensive and more sensitive tests to the clinic to improve patient care and outcome. With an initial focus on melanoma, our approach is easily expandable to other cancer types in the future. We are collaborating with leading cancer center in Europe and the US to achieve broad acceptance by the medical community.

More news about Oncobit AG

01.03.2024 10:30

Oncobit joins forces with Immunocore

Please login or
register to use the
awards follow feature
28.11.2022 09:25

Experienced managers and researchers join start-ups

Please login or
register to use the
awards follow feature
26.08.2022 08:39

Strong Swiss delegation at Medica

Please login or
register to use the
awards follow feature
03.06.2022 08:51

Milestone CE marking for Oncobit first product

Please login or
register to use the
awards follow feature
30.04.2021 15:23

Oncobit secures CHF 2.3 million seed financing round

Please login or
register to use the
awards follow feature
02.02.2021 13:30

Swiss startups braced for a virtual bootcamp in Boston and New York

Please login or
register to use the
awards follow feature
20.11.2020 11:19

Ventures for the Virtual Venture Day revealed

Please login or
register to use the
awards follow feature
Oncobit AG

Founded
2018

Kanton
ZH


LinkedIn

Homepage

rss